N
NewBridge Pharmaceuticals
Newbridge's core therapeutic areas of focus are oncology, cardiology, neurology, and rare diseases
About NewBridge Pharmaceuticals
NewBridge Pharmaceuticals is a specialty healthcare company focused on bridging the gap between global innovation and the MENA (Middle East and North Africa) region. The company provides a one-stop solution for pharmaceutical, biological, genomic, and other innovative healthcare companies seeking to access the MENA markets. NewBridge serves patients by offering advanced treatment options and addressing unmet medical needs in the region.
Operating in over 20 countries within the MENA region, NewBridge leverages its extensive global business network to provide essential access to innovative therapeutics and diagnostics. The company partners with leading pharmaceutics and biotech firms to bring cutting-edge healthcare solutions to the market.
NewBridge's business model revolves around forming strategic partnerships with global healthcare innovators, enabling them to penetrate the MENA market effectively. The company generates revenue through these partnerships by facilitating the distribution and commercialization of advanced healthcare products.
Clients of NewBridge include pharmaceutical companies, biotech firms, and healthcare providers looking to expand their reach in the MENA region. The company’s unique value proposition lies in its ability to navigate the complex regulatory landscape and provide market access solutions tailored to the needs of its partners.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Ajman, United Arab Emirates
- Employees
- 311
- Open positions
- 7
- Dealroom signal
- 85.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, Disease, Biotech and Pharma, Hard Tech, medical testing
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Mar 2013 | $48M | $192M | Kuwait Life Sciences Company · Revelation Partners · Burrill · Elan Corporation | ↗ |
| SERIES BOther financing | Sep 2010 | $12M | $48M | Burrill · Kuwait Life Sciences Company | ↗ |
Growth signals
Latest recorded traffic for NewBridge Pharmaceuticals is 2.1K monthly website visits, down 19.2% over the last three months. NewBridge Pharmaceuticals's team grew 9.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Burrill
Kuwait Life Sciences Company
Series B and later2 investors entered at this stage
Elan Corporation
Revelation Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NewBridge Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NewBridge Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.